Hema Focused

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/104

encourage image

There's no tags or description

Looks like no tags are added yet.

105 Terms

1
New cards

IDA - key investigations

CBC: low Hb, MCV < 80, MCH/MCHC low, RDW high; film: microcytic hypochromic, pencil cells; retics low/normal; serum iron low, TIBC high, ferritin low (< 13 ug/L), transferrin saturation low; find the source (stool occult blood, endoscopy)

2
New cards

IDA - best diagnostic test

Serum ferritin (most sensitive and specific); in inflammation ferritin < 30 suggests IDA, > 100 makes it unlikely

3
New cards

IDA - treatment

Treat the cause; oral ferrous sulfate 325 mg TDS (65 mg elemental iron) on an empty stomach with vitamin C for 3-6 months after Hb normalizes; IV iron (ferric carboxymaltose) if oral fails or not tolerated; transfusion only if Hb < 7 with compromise

4
New cards

IDA - important points

Most common anemia worldwide; koilonychia, pica, glossitis, angular stomatitis; Plummer-Vinson = web + dysphagia + IDA; Hb rises 1-2 g/dL every 2-3 weeks; retics peak at 7-10 days; Ganzoni formula for IV iron dose

5
New cards

Beta-thalassemia major - investigations

Hb 2-6, MCV 50-65, RDW normal; film: target cells, nucleated RBCs, tear drops; HPLC: HbF 60-90%, HbA2 high, little/no HbA; ferritin high; skull X-ray hair-on-end; MRI T2* of heart and liver

6
New cards

Beta-thalassemia major - treatment

Regular leukocyte-depleted transfusions every 3-4 weeks; folic acid 5 mg/day; iron chelation (deferoxamine, deferasirox, deferiprone); splenectomy for hypersplenism; curative: allogeneic SCT

7
New cards

Beta-thalassemia major - important points

Presents at 3-6 months when HbF falls; thalassemic facies; leading cause of death is iron-overload cardiomyopathy; start chelation at ferritin > 1000 or after 10-15 transfusions; MRI T2* is the gold standard for iron quantification

8
New cards

Beta-thalassemia minor - diagnosis and treatment

Mild anemia, low MCV, normal RDW, HbA2 > 3.5% (diagnostic), normal ferritin; no treatment needed; genetic counseling

9
New cards

Beta-thal minor vs IDA - important points

Beta-thal minor: RBC count HIGH, RDW normal, HbA2 > 3.5%, ferritin normal; IDA: RBC count low, RDW high, ferritin low

10
New cards

Alpha-thalassemia - diagnosis and treatment

HbH disease: Hb 7-11, retics 5-10%, brilliant cresyl blue shows golf-ball inclusions, HbH on HPLC; treat with intermittent transfusions, folic acid, chelation, splenectomy; Hb Barts hydrops: HPLC Hb Barts 70-90%, absent HbF, incompatible with life

11
New cards

Alpha-thalassemia - important points

4 alpha genes on chromosome 16; 1 deletion = silent carrier; 2 = trait; 3 = HbH disease; 4 = Hb Barts hydrops fetalis

12
New cards

Sideroblastic anemia/lead toxicity - diagnosis and treatment

Ringed sideroblasts (Prussian blue), basophilic stippling, HIGH iron and ferritin; remove lead source and give chelation; never give iron

13
New cards

Hemolysis - general diagnosis

Increased retics, indirect bilirubin, LDH; low haptoglobin; blood film for morphology; DAT (Coombs) to look for immune cause

14
New cards

Intravascular vs extravascular hemolysis - key differences

Intravascular: marked low haptoglobin, free plasma Hb, hemoglobinuria, marked LDH rise (e.g., G6PD, PNH, TTP); extravascular: normal/slightly low haptoglobin, no hemoglobinuria, mild LDH rise (e.g., HS, AIHA)

15
New cards

Hereditary spherocytosis - diagnosis and treatment

Normocytic anemia, spherocytes, extravascular hemolysis markers; osmotic fragility (increased) or EMA binding test; treat with folic acid and splenectomy (vaccinate first against pneumococcus, meningococcus, Hib)

16
New cards

Hereditary spherocytosis - important points

Autosomal dominant (75%); spectrin/ankyrin defect; complications: gallstones, aplastic crisis (parvovirus B19), megaloblastic crisis (folate)

17
New cards

G6PD deficiency - diagnosis and treatment

Film: Heinz bodies, bite and blister cells; G6PD enzyme assay AFTER the acute episode; supportive treatment: remove trigger, hydration, transfuse if severe

18
New cards

G6PD deficiency - important points

X-linked recessive; triggers: infections (most common), primaquine, dapsone, nitrofurantoin, rasburicase, sulfas, fava beans; mainly intravascular hemolysis; neonatal jaundice

19
New cards

Sickle cell disease - diagnosis

Hb electrophoresis is the gold standard (HbSS: HbS 80-95%, no HbA); HPLC for newborn screening; sickle solubility test is screening only; film: sickle cells, target cells, Howell-Jolly bodies

20
New cards

Sickle cell disease - long-term treatment

Vaccines (pneumococcal, Hib, meningococcal, hepatitis B); penicillin prophylaxis until at least age 5; folic acid 5 mg/day; hydroxyurea (raises HbF); transfusion for complications; curative: allogeneic SCT

21
New cards

Sickle cell disease - acute pain crisis treatment

Treat precipitants, analgesia by WHO ladder up to IV morphine, IV hydration (careful), oxygen if SpO2 < 95%, incentive spirometry

22
New cards

Sickle cell disease - important points

Glu to Val at beta-6; HbF inhibits sickling; dactylitis in infants; acute chest syndrome is the leading cause of death in adults; autosplenectomy by age 5; transcranial Doppler yearly in children 2-16

23
New cards

Hydroxyurea - important points

Raises HbF, lowers neutrophils; indicated for >= 3 crises/year, ACS, severe anemia; reduces crises by ~50%; side effects: myelosuppression and teratogenicity

24
New cards

Warm AIHA - diagnosis and treatment

IgG, DAT positive (IgG +/- C3d), spherocytes; prednisolone 1 mg/kg/day, then IVIG, rituximab, splenectomy

25
New cards

Cold AIHA - diagnosis and treatment

IgM, DAT positive for C3d only, agglutination on film; avoid cold, treat cause (Mycoplasma, EBV, lymphoma), rituximab; steroids usually ineffective

26
New cards

Direct vs indirect Coombs - important points

Direct: antibodies/complement on patient's RBCs (AIHA, transfusion reaction, HDN); indirect: patient's serum antibodies against donor RBCs (cross-matching)

27
New cards

MAHA/TTP - diagnosis

Schistocytes > 1% = MAHA until proven otherwise (emergency); TTP: severe thrombocytopenia, low ADAMTS13 activity (< 10%), normal PT/PTT and fibrinogen

28
New cards

TTP - treatment

Urgent plasma exchange; steroids and rituximab for acquired TTP; untreated TTP is 90% fatal

29
New cards

TTP vs DIC - important points

TTP: ADAMTS13 deficiency, normal PT/PTT/fibrinogen, plasma exchange; DIC: tissue factor activation, prolonged PT/PTT, low fibrinogen, treat the cause

30
New cards

Aplastic anemia - investigations

Pancytopenia, retics < 20 x 10^9/L, hypocellular marrow < 25% with fat replacement, no fibrosis or infiltration; normal karyotype; flow cytometry CD55/CD59 for PNH clone; viral serology; Fanconi screen (chromosomal breakage); HLA typing

31
New cards

Aplastic anemia - treatment

Supportive: transfuse (Hb > 8, platelets > 10) with irradiated CMV-negative products, infection prophylaxis; definitive: allogeneic SCT if < 40 with matched sibling; otherwise ATG + cyclosporine +/- eltrombopag

32
New cards

Aplastic anemia - important points

Immune-mediated (T cells, IFN-gamma, TNF-alpha); idiopathic 70%; chloramphenicol, benzene; no lymphadenopathy or splenomegaly (if present think leukemia/lymphoma); severe = marrow < 25% + 2 of 3 (neutrophils < 0.5, platelets < 20, retics < 20)

33
New cards

PNH - diagnosis and important points

Flow cytometry for CD55 and CD59; PIG-A mutation (no GPI anchor); chronic intravascular hemolysis, thrombosis (leading cause of death; Budd-Chiari), marrow failure; urinary iron loss causes iron deficiency

34
New cards

Anemia of chronic disease - diagnosis

Normal/low MCV, low iron, low/normal TIBC, normal/HIGH ferritin, HIGH hepcidin, normal sTfR, raised ESR/CRP; Hb usually 8-10

35
New cards

Anemia of chronic disease - treatment

Treat the underlying disease; ESAs in CKD or chemotherapy (target Hb 10-12); IV iron if coexistent IDA; transfusion if Hb < 7-8 and symptomatic; oral iron is not helpful

36
New cards

Anemia of chronic disease - important points

Second most common anemia; IL-6 raises hepcidin, which degrades ferroportin and traps iron; sTfR/log ferritin > 2 suggests coexistent IDA

37
New cards

Megaloblastic anemia - investigations

MCV > 100; hypersegmented neutrophils (pathognomonic) and macro-ovalocytes; low retics; low B12 (< 200 pg/mL); RBC folate; MMA high ONLY in B12 deficiency; homocysteine high in both; high LDH; anti-parietal cell and anti-intrinsic factor antibodies

38
New cards

Megaloblastic anemia - treatment

B12: IM hydroxocobalamin 1000 ug daily x 7 days, weekly x 4, then every 3 months for life; folate: folic acid 5 mg daily for 4 months; NEVER give folate alone before treating B12 deficiency

39
New cards

Megaloblastic anemia - important points

Pernicious anemia is the most common cause of B12 deficiency in adults; B12 deficiency causes subacute combined degeneration; retics peak at 5-7 days; watch for hypokalemia at start; gastric cancer surveillance in pernicious anemia

40
New cards

MDS - diagnosis

Macrocytic anemia with cytopenias; dysplasia on smear (pseudo-Pelger-Huet, hypogranular neutrophils); hypercellular marrow with dysplasia; cytogenetics del(5q), del(7q); exclude megaloblastic anemia first

41
New cards

MDS - important points

Rich marrow, poor blood (intramedullary apoptosis); age > 50; risk of transformation to AML; caused by benzene, radiation, prior chemotherapy

42
New cards

Anemia of CKD - treatment and important points

Main cause is EPO deficiency; normocytic normochromic; treat with EPO, correct iron and folate, transfuse if symptomatic

43
New cards

Normal hemostasis - important points

Vasoconstriction, primary hemostasis (platelet plug via vWF), secondary hemostasis (fibrin via coagulation cascade), then fibrinolysis by plasmin

44
New cards

PT vs aPTT - important points

PT = extrinsic (factor VII) and common pathway; aPTT = intrinsic (VIII, IX, XI, XII) and common pathway

45
New cards

Vascular bleeding disorders - diagnosis

Mucocutaneous bleeding with NORMAL platelet count and coagulation tests; examples: HHT, scurvy, Henoch-Schonlein purpura, senile and steroid purpura

46
New cards

Thrombocytopenia - important points

< 150 x 10^9/L; spontaneous bleeding < 20; life-threatening < 5; mechanisms: decreased production, increased destruction, sequestration, hemodilution
47
New cards

ITP - diagnosis

Diagnosis of exclusion; isolated thrombocytopenia with large platelets on smear; exclude secondary causes (ANA, antiphospholipid antibodies, HCV, HIV, H. pylori); marrow only if atypical or refractory (normal/increased megakaryocytes)

48
New cards

ITP - treatment

Corticosteroids 1 mg/kg/day; IVIG for rapid rise; TPO agonists (romiplostim, eltrombopag); splenectomy if other treatments fail

49
New cards

ITP - important points

IgG autoantibodies against platelet glycoproteins; children: acute, post-infection, 90% spontaneous remission; adults: insidious, chronic, F:M 3:1; Evans syndrome = ITP + AIHA

50
New cards

TTP - important points

ADAMTS13 deficiency leads to ultra-large vWF multimers and microthrombi; pentad features: thrombocytopenia, hemolysis, brain ischemia, fever, renal involvement; plasma exchange is the primary treatment

51
New cards

Thrombasthenia - diagnosis and important points

Normal platelet count with abnormal PFA-100; light transmission aggregometry and flow cytometry; Glanzmann = GP IIb/IIIa defect; Bernard-Soulier = GP Ib/IX/V defect and large platelets; aspirin and NSAIDs are the commonest cause

52
New cards

von Willebrand disease - diagnosis

Normal platelet count, abnormal PFA-100, aPTT normal or prolonged; VWF antigen, VWF activity (ristocetin cofactor), and FVIII binding

53
New cards

von Willebrand disease - treatment and important points

DDAVP is effective in type 1; most common inherited bleeding disorder (autosomal dominant); type 1 mild-moderate deficiency, type 2 defective function, type 3 near absent; mucocutaneous bleeding

54
New cards

Hemophilia A - diagnosis

Prolonged aPTT, normal PT, normal platelet count, low factor VIII assay (severity: mild > 5%, moderate 1-5%, severe < 1%)

55
New cards

Hemophilia A - treatment

Recombinant factor VIII concentrate (prophylaxis is superior to on-demand); DDAVP for mild disease; tranexamic acid; FFP or cryoprecipitate if concentrate is not available

56
New cards

Hemophilia B - important points

Factor IX deficiency; treated with factor IX concentrate; DDAVP not effective; cryoprecipitate cannot be used (no factor IX)

57
New cards

Hemophilia vs VWD - important points

Hemophilia: X-linked, hemarthrosis, normal platelet function, prolonged aPTT, normal vWF; VWD: autosomal dominant, mucocutaneous bleeding, abnormal platelet function, decreased vWF

58
New cards

Factor inhibitors - diagnosis and treatment

Diagnosed by aPTT mixing study (fails to correct); treat with bypassing agents (rFVIIa, aPCC) and immunosuppression

59
New cards

Bleeding patient - important points

Best predictor is a detailed history; skin/mucosal bleeding suggests platelet or vascular problem; deep joint/muscle bleeding suggests coagulation defect; petechiae highly suggest platelet disorder

60
New cards

Coagulation screening - interpretation

Prolonged PT = factor VII, VKA, vitamin K deficiency; prolonged aPTT = VIII, IX, XI, XII, vWD, heparin, lupus anticoagulant; both prolonged = V, X, II, I, DIC, advanced liver disease; normal tests with bleeding = VWD, factor XIII deficiency

61
New cards

VTE - diagnosis

D-dimer (negative has high NPV, positive is nonspecific); venous duplex = gold standard for DVT; CT pulmonary angiography for PE (V/Q scan alternative); CT venography for atypical sites

62
New cards

VTE - treatment

Anticoagulation: LMWH 1 IU/kg SC BID or UFH (monitor aPTT); warfarin (INR 2-3) or DOACs (rivaroxaban, apixaban, dabigatran - preferred); DVT 3 months, PE up to 6 months; rtPA for hypotensive PE

63
New cards

VTE - important points

Virchow's triad: endothelial injury, stasis, hypercoagulability; provoked vs unprovoked; transient factors: surgery, OCP, pregnancy, immobility; persistent: active cancer

64
New cards

Thrombophilia - who to test

Unprovoked VTE before age 45, family history with management impact, unusual-site thrombosis, warfarin-induced skin necrosis, recurrent miscarriage; do NOT test provoked VTE or arterial thrombosis routinely

65
New cards

Thrombophilia - important points

Hereditary: protein C, protein S, antithrombin deficiency, factor V Leiden, prothrombin mutation; acquired: HIT, antiphospholipid syndrome, PNH, MPN; heritable thrombophilia alone is not an indication for anticoagulation

66
New cards

Thrombophilia - special treatment situations

HIT: stop heparin and use argatroban; protein C/S deficiency: DOAC rather than warfarin; antiphospholipid syndrome: warfarin indefinitely (not DOAC)

67
New cards

Anticoagulation duration - important points

Provoked: 3 months (6 if cancer); unprovoked: 3-6 months then consider indefinite low-dose DOAC; recurrent VTE or antiphospholipid syndrome: indefinite

68
New cards

AML - diagnosis

Blasts > 20% in marrow (or myeloblasts in blood); immunophenotyping CD13 and CD33; cytogenetics for prognosis; raised LDH, uric acid; echo before chemotherapy

69
New cards

AML - treatment

Supportive (transfusions, antibiotics, leukapheresis for hyperleukocytosis); induction with cytarabine-based chemotherapy; consolidation with cytarabine cycles or allogeneic SCT in high-risk or relapsed disease

70
New cards

AML - important points

M3 (APL) causes DIC and has t(15;17) PML/RARA; M4 and M5 infiltrate gums and CNS; complications: leukostasis, tumor lysis syndrome; splenomegaly and lymphadenopathy uncommon

71
New cards

ALL - diagnosis

Lymphoblasts > 20% in marrow; CD19/CD20 (B-ALL), CD3/CD2/CD7 (T-ALL); CSF analysis, MRI brain/spine, CT chest, scrotal ultrasound

72
New cards

ALL - treatment

Multiagent chemotherapy plus maintenance for at least 2 years; intrathecal CNS prophylaxis is critical; allogeneic SCT for high-risk adults or relapsed disease

73
New cards

ALL - important points

Most common childhood malignancy; lymphadenopathy, splenomegaly, anterior mediastinal mass (T-ALL); testicular and CNS involvement carry poor prognosis; t(9;22) BCR-ABL1 is a high-risk abnormality

74
New cards

CML - diagnosis

WBC often > 100 with all stages of granulocyte maturation; platelets normal or high; hypercellular marrow with blasts < 5%; BCR-ABL1 t(9;22) by cytogenetics or RT-PCR

75
New cards

CML - treatment

Hydroxyurea for cytoreduction; tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib); allogeneic HCT

76
New cards

CML - important points

Philadelphia chromosome; phases: chronic (< 10% blasts), accelerated (10-19%), blastic (> 20%); 95% diagnosed in chronic phase; splenomegaly

77
New cards

CLL - diagnosis

Sustained monoclonal lymphocytes > 5 x 10^9/L; flow cytometry CD19+, CD20+, CD5+, CD23+ with weak surface Ig; smudge cells; marrow >= 30% lymphocytes; DAT if hemolysis suspected; immunoglobulin levels

78
New cards

CLL - treatment

Watchful waiting if asymptomatic; treat for B symptoms, rapid lymphocyte doubling (< 6 months), progressive lymphadenopathy/splenomegaly, or cytopenias; options: chemo (cyclophosphamide, bendamustine), ibrutinib (BTK inhibitor), rituximab

79
New cards

CLL - important points

Mature B cell malignancy; median age 70; usually asymptomatic; hypogammaglobulinemia causes infections; AIHA in ~10%; small, rubbery, non-tender nodes

80
New cards

Polycythemia vera - diagnosis

Hb > 16.5 (men) or > 16.0 (women) or Hct > 49%/48%; low/normal EPO; JAK2 V617F (> 98%); normal O2 saturation; hypercellular marrow with panmyelosis

81
New cards

Polycythemia vera - treatment

Aspirin 80-100 mg for all; phlebotomy to Hct < 45%; hydroxyurea, ruxolitinib, or ropeginterferon for myelosuppression

82
New cards

Polycythemia vera - important points

Aquagenic pruritus after hot bath; hyperviscosity and thrombosis; splenomegaly in 75%; differentiate from secondary erythrocytosis (hypoxia, EPO-secreting tumors)

83
New cards

Essential thrombocythemia - diagnosis and treatment

Platelets >= 450; marrow with clusters of mature megakaryocytes; JAK2, CALR, or MPL mutations (~80%); exclude reactive causes; treat with aspirin, hydroxyurea first-line, anagrelide second-line

84
New cards

Essential thrombocythemia - important points

Arterial more than venous thrombosis; bleeding when platelets > 1000 (acquired vWD); recurrent miscarriage from placental infarcts

85
New cards

Primary myelofibrosis - diagnosis and treatment

Leucoerythroblastic film with teardrop cells; dry tap; reticulin fibrosis on biopsy; treat with supportive care, ruxolitinib (JAK2 inhibitor), splenectomy/irradiation, allogeneic HSCT

86
New cards

Primary myelofibrosis - important points

Massive splenomegaly in virtually all; fibrosis from cytokines released by megakaryocytes; ~30% JAK2 V617F; 15% transform to acute leukemia

87
New cards

Generalized lymphadenopathy - approach

History (course, B symptoms, exposures, drugs), exam (hard/fixed/matted = malignant; soft/tender/mobile = infectious), CBC and smear, LDH, uric acid, HIV/EBV/CMV, CT, PET-CT; excisional biopsy is the gold standard

88
New cards

Hodgkin lymphoma - diagnosis

Excisional lymph node biopsy showing Reed-Sternberg cells; PET/CT and CT for staging (Ann Arbor); raised ESR and LDH are adverse; marrow biopsy only in stage III-IV, bulky disease, or cytopenia

89
New cards

Hodgkin lymphoma - treatment

Stage I-II: 2 cycles ABVD plus involved-field radiotherapy; stage III-IV: 6 cycles ABVD (+/- brentuximab vedotin anti-CD30); relapse: high-dose chemotherapy and transplant

90
New cards

Hodgkin lymphoma - important points

Bimodal age peaks (20 and > 50); EBV in up to 50%; nodular sclerosis most common (60-80%); lymphocyte-depleted has the worst prognosis; rubbery painless nodes; B symptoms and pruritus

91
New cards

NHL - diagnosis

Excisional biopsy (FNA unreliable); immunophenotyping, cytogenetics; labs: LDH, uric acid, beta-2 microglobulin, immunoglobulins, HIV, hepatitis B; imaging: CT and PET; marrow for staging

92
New cards

NHL - treatment

Depends on stage, grade, and phenotype; CHOP or CVP chemotherapy; add rituximab (anti-CD20) for B-cell lymphomas; low-grade asymptomatic = watch and wait

93
New cards

NHL - important points

85% B-cell; indolent (follicular, SLL/CLL), aggressive (DLBCL), highly aggressive (Burkitt); t(14;18) follicular, t(8;14) Burkitt, t(11;14) mantle cell; H. pylori and gastric lymphoma; tumor lysis risk; check hepatitis B before rituximab

94
New cards

Multiple myeloma - diagnosis

Marrow plasma cells >= 10% plus a myeloma-defining event (CRAB or marrow plasma cells >= 60%, FLC ratio >= 100, > 1 focal MRI lesion); SPEP/UPEP, immunofixation, free light chains; skeletal survey, MRI, or PET/CT

95
New cards

Multiple myeloma - treatment

Supportive: hydration, bisphosphonates/denosumab, treat hypercalcemia, plasmapheresis for hyperviscosity; induction with bortezomib + lenalidomide + steroids; autologous SCT for eligible patients; lenalidomide maintenance

96
New cards

Multiple myeloma - important points

Bone pain most common symptom; ESR often > 100; rouleaux and M protein; renal failure from cast nephropathy; recurrent pneumococcal infections; solitary plasmacytoma treated with radiotherapy

97
New cards

MGUS vs smoldering vs myeloma - important points

MGUS: M-protein < 3 g/dL and marrow plasma cells < 10%, most common, observe; smoldering: > 3 g/dL or 10-60% plasma cells without CRAB, monitor; active myeloma: myeloma-defining event, treat

98
New cards

Transfusion indications - important points

RBC: acute loss, Hb < 7 (target >= 9 in elderly/cardiac); FFP: factor deficiency, warfarin overdose, liver disease, DIC, TTP; platelets: < 10 x 10^3, bleeding with low platelets, thrombasthenia

99
New cards

Acute hemolytic transfusion reaction - management

ABO incompatibility; stop transfusion immediately, send unit to blood bank for recross-matching; evidence: increased bilirubin, positive direct Coombs, hemoglobinuria

100
New cards

Febrile non-hemolytic reaction - important points

Most common reaction; cytokines from stored WBCs; diagnosis of exclusion; treat with antipyretics